2019 ESC Guidelines for the Diagnosis and Management of Acute Pulmonary Embolism: Habemus (Novam) Lex!

1. Guyatt GH. Evidence-based medicine. ACP J Club 1991; 114: A16.10.7326/ACPJC-1991-114-2-A16Search in Google Scholar

2. Sehon SR, Stanley DE. A philosophical analysis of the evidence-based medicine debate. BMC Health Services Research 2003; 3: 14.10.1186/1472-6963-3-1416918712873351Search in Google Scholar

3. Konstantinides SV, Meyer G, Becattini C et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Heart J 2019; 00: 161 doi:10.1093/eurheartj/ehz405.10.1093/eurheartj/ehz40531504429Search in Google Scholar

4. Beydilli İ, Yılmaz F, Sönmez BM, et al. Thrombolytic therapy delay is independent predictor of mortality in acute pulmonary embolism at emergency service. Kaohsiung J Med Sci 2016; b32 (11): b572-578.10.1016/j.kjms.2016.09.00427847100Search in Google Scholar

5. Agnelli G, Becattini C, Bauersachs R, et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: The Caravaggio Study. Thromb Haemost 2018; 118(9): 1668-1678.10.1055/s-0038-166852330103252Search in Google Scholar

6. Napolitano M, Saccullo G, Malato A, et al. Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study. J Clin Oncol 2014; 32: 3607-3612.10.1200/JCO.2013.51.743325267738Search in Google Scholar

7. Rosovsky R, Borges J, Kabrhel C, Rosenfield K. Pulmonary embolism response team: inpatient structure, outpatient follow-up, and is it the current standard of care? Clin Chest Med 2018; 39: 62130.Search in Google Scholar